This leading pharmaceutical stock is flying under the radar right now.Eli Lilly (LLY 0.21%) is hogging the headlines as its market capitalization marches toward $1 trillion. But even as the market continues to evaluate the growing demand for anti-obesity drugs and bids up businesses in the weight-loss space, it could be ignoring other businesses in the pharma industry. As a result, quite a few pharmaceutical stocks are currently flying under the market's radar, and investors could be looking at solid opport ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $161.43, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.57%.Shares of the world's biggest maker of health care products witnessed a gain of 5.13% over the previous month, beating the performance of the Medical sector with its gain of 4.9% and the S&P 500's gain of 1.77%.Market par ...

Core Viewpoint - Johnson & Johnson (JNJ) has announced a definitive agreement to acquire V-Wave Ltd. for an initial payment of $600 million, aiming to enhance its MedTech business in the cardiovascular sector [1][2]. Group 1: Acquisition Details - JNJ will acquire V-Wave, which is focused on innovative treatments for heart failure, specifically through its Ventura Interatrial Shunt (IAS) device [1]. - The Ventura IAS has received Breakthrough Device Designation from the FDA and is positioned to be the first device targeting heart failure with reduced ejection fraction (HFrEF) [1]. - The total potential payments to V-Wave could reach approximately $1.1 billion, including regulatory and commercial milestones [1]. Group 2: Strategic Fit and Market Potential - The acquisition is seen as a strategic fit for JNJ, expected to strengthen its position in the cardiovascular disease market, which affects nearly 800,000 patients with HFrEF annually in the U.S. [2]. - JNJ's MedTech segment has been actively expanding, having previously acquired Shockwave Medical and Abiomed to enhance its portfolio in high-growth cardiovascular markets [2][3]. Group 3: Financial Performance and Projections - In the first half of 2024, JNJ's MedTech business reported sales of $15.8 billion, reflecting a year-over-year increase of 3.3% and an operational increase of 5.4% [3]. - The MedTech segment is projected to grow by 6% in 2024 [3].

Johnson & Johnson (JNJ) announced that the FDA approved the combination of its intravenously administered EFGR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitor Lazcluze (lazertinib) as a chemotherapy-free treatment for a type of lung cancer.Following the FDA decision, Rybrevant combined with Lazcluze is approved as a first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutation ...

Key TakeawaysJohnson & Johnson made a pair of announcements Tuesday: Federal Drug Administration (FDA) approval of a new lung cancer treatment and an acquisition.The FDA approved a pair of drugs as a form of chemotherapy-free lung cancer treatment after a Phase 3 clinical trial showed the drugs reduce the risk of death or disease progression by 30% compared with the current standard of care.Johnson & Johnson also announced the $1.7 billion acquisition of privately-held V-Wave, expanding the company's offeri ...

RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinibFollowing Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of responseRARITAN, N.J., Aug. 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration ( ...

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 2.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales Top, EPS Guidance Cu ...

Torsten Asmus/iStock via Getty Images This article was inspired by a request from one of our members who was interested in an overview of the healthcare sector. Request granted! I am an inveterate grader of dividend-growth stocks. Several years ago, I created a reasonably fast way to get a general idea about the quality of a dividend-growth company: Quality Snapshots. Speaking as a dividend-growth investor, quality refers to a company's ability to: Consistently generate strong financial performance Maintai ...

Blue-chip stocks are commanding attention from investors looking for stability and reliability amidst a fluctuating market. Typically, these stock market stalwarts are known for their solid financials, long histories of profitability and consistent records of dividend payments. These factors make them perennial favorites among conservative investors.The stock market has been volatile of late as investors mull over the possibility of a hard landing. This has led to a decline in stock prices of several compan ...

Johnson & Johnson has cleared a key threshold of support for its proposed $6.5-billion settlement of tens of thousands of lawsuits alleging its baby powder and other talc products caused cancer, according to a Bloomberg report. More than 75% of claimants voted in favor of the proposal, according to Bloomberg, a hurdle J&J set for a third attempt at placing a subsidiary in bankruptcy protection to resolve the litigation.Reuters has not independently verified the report, for which Bloomberg cited sources fami ...